~~<i id='5D9E29A97C'><strike id='5D9E29A97C'><tt id='5D9E29A97C'><pre id='5D9E29A97C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

focus

author：Wikipedia 2025-09-30 18:21:21 - browse：3

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Biogen nominates mother of director’s child to replace him on board

focus

Wikipedia

explore

focus

entertainment

focus

APStockWASHINGTON—AfederaldistrictjudgeonMondaygrantedtheBidenadministration’srequesttodismissalawsu

WSS

Biogen Alzheimer’s drug launch off to slow start

The thinking behind the controversial eating disorder chatbot Tessa

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Biden administration plans revamp of organ transplant system

explore

focus

focus

Hepatitis C has a cure — but many Americans still lack access to it

Medicare Advantage proposed rates disappoint insurers

Hollywood unions extend contract negotiations for actors

Biden report: The neurospychology of memory and aging

How to save PrEP access — and even expand it

Timeline: Key moments in fight for gay rights

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Senate panel passes drug pricing bills, but drops one PBM reform

Walensky prepares to leave CDC — and Congress — behind

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Wikipedia

Private equity deals in Medicare Advantage declines

To avoid data mishandling cases, universities eye AI and other tools

Novo pauses ads for weight loss drug Wegovy amid demand

Novo pauses ads for weight loss drug Wegovy amid demand

Can medical device makers keep up in the race to treat obesity?

For Medicare Advantage, Democrats want stronger protections around AI

explore

focus

entertainment

focus